A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Recreational use == In 1979, the first case of xylazine toxicity was reported in a 34-year-old male who had self-medicated for insomnia with an injection of 1g of xylazine. In the US, Xylazine is not regulated as a controlled substance under the Controlled Substances Act. It is sold online through distributors often without requiring proof of a veterinary license. The cost to purchase Xylazine from overseas suppliers is around $6–20 per kilogram. This low price makes it attractive for dealers looking for a cheap additive that is addictive and not treatable with opiate withdrawal medications. The withdrawal can last for two weeks and has a quicker onset than fentanyl. As an adulterant, xylazine is most commonly ingested with fentanyl. Xylazine has also been reported in combination with medetomidine, another potent α2-adrenergic receptor agonist. It is unknown if drug users are ingesting it knowingly. As of 2024, Seattle police report that some users wrongly believe they are consuming higher-quality fentanyl. Xylazine's street name in Puerto Rico is anestesia de caballo, which translates to "horse anesthetic". From 2002 to 2008, its use was associated with a high number of inmate deaths at the Guerrero Correctional Institution in Aguadilla, Puerto Rico. Xylazine's street name in the United States, particularly when it is mixed with fentanyl, is "tranq", "tranq dope" and "zombie drug". As of 2012, xylazine users in Puerto Rico were more likely to be male, under age 30, living in a rural area, and injecting rather than inhaling xylazine.
Major Charles Karu Singleton, The Princess of Wales's Royal Regiment, 565366. Staff Sergeant Charlotte Louise Spence, Royal Army Physical Training Corps, W1060016. Major Jonathan Grant Studwell, Intelligence Corps, 30170101. Major Thomas Daniel Sweeney, Army Air Corps, 24757307. Sergeant Edward William Swindell, , Corps of Royal Engineers, Army Reserve, 30150063. Major Francesca Louise Sykes, Royal Regiment of Artillery, 30067880. Lieutenant Colonel Andrew James Teeton, Corps of Royal Engineers, 536346. Major (now Acting Lieutenant Colonel) James Viney, Corps of Royal Engineers, 25185183. Captain (now Acting Major) David Edward Williams, Corps of Royal Electrical and Mechanical Engineers, 24929032. Master Aircrew Oliver Martin Dewey, Royal Air Force, 30060196. Sergeant (now Acting Flight Sergeant) George Joseph Downey, Royal Air Force, L8516771. Wing Commander Sam Haley, Royal Air Force, 30000089. Squadron Leader James Duncan Hemingfield, Royal Air Force, 8700294K. Sergeant Martin John Henderson, Royal Air Force, 30112261. Squadron Leader Sharon Ingle, Royal Air Force, 30091084. Flight Sergeant (now Acting Warrant Officer) Stewart Marcus Jackson, Royal Air Force, F8427999. Flight Sergeant Philip Kipling, Royal Air Force, D8411323. Squadron Leader Kevin Charles William March, Royal Air Force, 30035301. Squadron Leader Christopher Scott Middleton, Royal Air Force, 2642751S. Squadron Leader Mark Shipley, Royal Air Force, 30001963. Warrant Officer Garry John Stanton, Royal Air Force, K8421673.
=== Imaging Methods Core Facility === The Integrated Microscopy Core Facility (IMCF) provides fluorescence microscopy, electron microscopy, and flow cytometry services. The facility offers training, instrument access, and consulting services for experimental design, sample preparation, and data analysis. It also organizes courses on microscopic techniques.
Posaconazole, sold under the brand name Noxafil among others, is a triazole antifungal medication. It was approved for medical use in the European Union in October 2005, and in the United States in September 2006. It is available as a generic medication.
Sources: en.wikipedia.org
The advantages of supercritical fluid extraction (compared with liquid extraction) are that it is relatively rapid because of the low viscosities and high diffusivities associated with supercritical fluids. Alternative solvents to supercritical fluids may be poisonous, flammable or an environmental hazard to a much larger extent than water or carbon dioxide are. The extraction can be selective to some extent by controlling the density of the medium, and the extracted material is easily recovered by simply depressurizing, allowing the supercritical fluid to return to gas phase and evaporate leaving little or no solvent residues. Carbon dioxide is the most common supercritical solvent. It is used on a large scale for the decaffeination of green coffee beans, the extraction of hops for beer production, and the production of essential oils and pharmaceutical products from plants. A few laboratory test methods include the use of supercritical fluid extraction as an extraction method instead of using traditional solvents.
=== Transportation companies === Canadian Airlines (1987–2001) (IATA airline code CP) Canadian Pacific Railway, reporting mark CP Central Pacific Railroad, a network of lines between California and Utah, US Chemins de Fer de Provence, a French public railway company Comboios de Portugal, a Portuguese state-owned train company CP Air or Canadian Pacific Air Lines (1942–1987), a Canadian airline CP Ships, a Canadian shipping company, part of TUI Group Cathay Pacific, a Hong Kong–based major airline
Labour defeated the Conservatives by four seats in the British general election on 15 October 1964, and formed a government the next day. Both Labour and the Conservatives told Smith that a positive result at the indaba would not be recognised by Britain as representative of the people, and the Conservatives turned down Salisbury's invitation to send observers. Smith pressed on, telling parliament that he would ask the tribal chiefs and headmen "to consult their people in the traditional manner", then hold the indaba as planned. On 22 October 196 chiefs and 426 headmen from across the country gathered at Domboshawa, just north-east of Salisbury, and began their deliberations. Smith hoped that Britain, having taken part in such indabas in the past, might send a delegation at the last minute, but none arrived, much to his annoyance, particularly as the British government's Commonwealth Secretary Arthur Bottomley was only across the Zambezi in Lusaka at the time. While the chiefs conferred, Northern Rhodesia became independent Zambia on 24 October 1964, emulating Nyasaland, which had achieved statehood as Malawi three months earlier. Reasoning that it was no longer necessary to refer to itself as "Southern" in the absence of a northern counterpart, Southern Rhodesia began calling itself simply Rhodesia. The same day, the commander of the Rhodesian Army, Major-General John "Jock" Anderson, resigned, announcing publicly that he was forced to do so because of his opposition to UDI, which he said he could not go along with because of his oath of allegiance to the Queen.
Furthermore, several newer studies have documented the substantial benefits of cold exposure in multiple species including humans, for example researchers concluded that "activation of brown adipose tissue is a powerful therapeutic avenue to ameliorate hyperlipidaemia and protect from atherosclerosis" and that brown fat activation reduces plasma triglyceride and cholesterol levels and attenuates diet-induced atherosclerosis development. Long-term studies of adult humans are needed to establish a balance of benefit and risk, in combination with historical research of living conditions of recent human generations prior to the current increase of poor health related to excessive accumulation of white fat. Pharmacological approaches using β3-adrenoceptor agonists have been shown to enhance glucose metabolic activity of brown adipose tissue in rodents. Additionally research has shown:
In the United States between 2020 and 2022, the number of e-cigarettes sold had climbed to 22.7 million units. Elf Bar/EBDESIGN, Vuse, JUUL, NJOY and Breeze Smoke were recognized as the five most popular brands as of December 2022. The surge was driven by non-tobacco flavors such as menthol (for prefilled cartridges) and fruit and candy (for disposables), according to the CDC's health economist Fatma Romeh Ali. In the UK, where most vaping uses refillable sets and e-liquid, there is now support from the National Health Service, and other medical bodies now embrace the use of e-cigarettes as a viable way to quit smoking. This has contributed to record numbers of people vaping, with an estimated 3.6 million in 2021. Nationally, about 7% of children and teenagers (aged 11–17) currently vape, which equates to roughly 400,000 children in Great Britain. Additionally, around 20% of young people have tried vaping at least once. Many vape brands are popular such as Lost mary Bm600 disposables (one use products) and The R and M Tornado 9000. "In 2025, reports highlighted the rise of illegal 'mega vapes' being sold to minors."
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.